CoChat

Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides

Open access
Lo, Yu-Li, Liu, Yu · 2014 · PLoS ONE

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Abstract

Multidrug resistance (MDR) is a major impediment to chemotherapy. In the present study, we designed antisense oligonucleotides (ASOs) against MDR1, MDR-associated protein (MRP)1, MRP2, and/or BCL-2/BCL-xL to reverse MDR transporters and induce apoptosis, respectively. The cationic liposomes (100 nm) composed of N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride and dioleoyl phosphotidylethanolamine core surrounded by a polyethylene glycol (PEG) shell were prepared to carry ASOs and/or epirubicin, an antineoplastic agent. We aimed to simultaneously suppress efflux pumps, provoke apoptosis, and enhance the chemosensitivity of human colon adenocarcinoma Caco-2 cells to epirubicin. We evaluated encapsulation efficiency, particle size, cytotoxicity, intracellular accumulation, mRNA levels, cell cycle distribution, and caspase activity of these formulations. We found that PEGylated liposomal ASOs significantly reduced Caco-2 cell viability and thus intensified epirubicin-mediated apoptosis. These formulations also decreased the MDR1 promoter activity levels and enhanced the intracellular retention of epirubicin in Caco-2 cells. Epirubicin and ASOs in PEGylated liposomes remarkably decreased mRNA expression levels of human MDR1, MRP1, MRP2, and BCL-2. The combined treatments all significantly increased the mRNA expressions of p53 and BAX, and activity levels of caspase-3, -8, and -9. The formulation of epirubicin and ASOs targeting both pump resistance of MDR1, MRP1, and MRP2 and nonpump resistance of BCL-2/BCL-xL demonstrated more superior effect to all the other formulations used in this study. Our results provide a novel insight into the mechanisms by which PEGylated liposomal ASOs against both resistance types act as activators to epirubicin-induced apoptosis through suppressing MDR1, MRP1, and MRP2, as well as triggering intrinsic mitochondrial and extrinsic death receptor pathways. The complicated regulation of MDR highlights the necessity for a multifunctional approach using an effective delivery system, such as PEGylated liposomes, to carry epirubicin and ASOs as a potent nanomedicine for improving the clinical efficacy of chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0090180

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The formation of PEGylated liposomal delivery system of epirubicin and antisense oligonucleotides and particle size distribution of this system. (A) A schematic diagram for the formation of PEGylated liposomal delivery system containing epirubicin (Epi) combined with antisense oligonucleotides (ASOs) targeting MDR1, MRP1, MRP2, and/or BCL-2/BCL-xL to reverse pump and nonpump resistances, respectively. (B) Particle size distribution of liposomal Epi combined with ASOs targeting MDR1, MRP1, MRP2, and BCL-2/BCL-xL.
Figure 1 The formation of PEGylated liposomal delivery system of epirubicin and antisense oligonucleotides and particle size distribution of this system. (A) A schematic diagram for the formation of PEGylated liposomal delivery system containing epirubicin (Epi) combined with antisense oligonucleotides (ASOs) targeting MDR1, MRP1, MRP2, and/or BCL-2/BCL-xL to reverse pump and nonpump resistances, respectively. (B) Particle size distribution of liposomal Epi combined with ASOs targeting MDR1, MRP1, MRP2, and BCL-2/BCL-xL.CC BY · PubMed Central
Figure 2 Susceptibility of Caco-2 cells after epirubicin and/or antisense oligonucleotide treatment. (A) The effect of Epi at concentrations 0, 0.1, 1, 5, 10, and 20 µg/ml for 48 h incubation on the cell viability of Caco-2 cells. * P<0.05, ** P<0.01, and *** P<0.001 compared to control (CTR). (B) The effect of Lip-ASOs against both resistance types at concentrations of 0, 0.1, 0.22, 0.44, 0.88, and 1.76 µM and 48 h of incubation on the cell viability of Caco-2 cells. * P<0.05 compared to CTR. (C) The effect of Epi (1 µg/ml) and ASOs (0.88 µM) in free or liposomal formulations on the cell viability of Caco-2 cells. Means ± S.D. from six independent experiments are shown. * P<0.05, ** P<0.01, and *** P<0.001 compared to CTR; † P<0.05 and †† P<0.01 compared to Epi; # P<0.05 when Lip-Epi+ASOs against both resistances compared to Lip-Epi+ASOs against pump resistance; § P<0.05 when Lip-Epi+ASOs against both resistances compared to Lip-Epi+ASOs against nonpump resistance.
Figure 2 Susceptibility of Caco-2 cells after epirubicin and/or antisense oligonucleotide treatment. (A) The effect of Epi at concentrations 0, 0.1, 1, 5, 10, and 20 µg/ml for 48 h incubation on the cell viability of Caco-2 cells. * P<0.05, ** P<0.01, and *** P<0.001 compared to control (CTR). (B) The effect of Lip-ASOs against both resistance types at concentrations of 0, 0.1, 0.22, 0.44, 0.88, and 1.76 µM and 48 h of incubation on the cell viability of Caco-2 cells. * P<0.05 compared to CTR. (C) The effect of Epi (1 µg/ml) and ASOs (0.88 µM) in free or liposomal formulations on the cell viability of Caco-2 cells. Means ± S.D. from six independent experiments are shown. * P<0.05, ** P<0.01, and *** P<0.001 compared to CTR; † P<0.05 and †† P<0.01 compared to Epi; # P<0.05 when Lip-Epi+ASOs against both resistances compared to Lip-Epi+ASOs against pump resistance; § P<0.05 when Lip-Epi+ASOs against both resistances compared to Lip-Epi+ASOs against nonpump resistance.CC BY · PubMed Central
Figure 3 The effect of different treatments on the mRNA levels of pump resistance associated genes. The effect of different treatments on the mRNA levels of MDR1, MRP1, and MRP2, as measured by real-time PCR. Means ± S.D. from three independent experiments are shown. * P<0.05 compared to CTR; † P<0.05 compared to Epi; ‡ P<0.05 when liposomal formulation compared to its corresponding free formulation. For example, Lip-ASOs against pump resistance vs ASOs against pump resistance. § P<0.05 when liposomal formulation of Epi plus ASOs compared to its corresponding liposomal formulation of ASOs. For example, Lip-Epi+ASOs against both resistances vs Lip-ASOs against both resistances.
Figure 3 The effect of different treatments on the mRNA levels of pump resistance associated genes. The effect of different treatments on the mRNA levels of MDR1, MRP1, and MRP2, as measured by real-time PCR. Means ± S.D. from three independent experiments are shown. * P<0.05 compared to CTR; † P<0.05 compared to Epi; ‡ P<0.05 when liposomal formulation compared to its corresponding free formulation. For example, Lip-ASOs against pump resistance vs ASOs against pump resistance. § P<0.05 when liposomal formulation of Epi plus ASOs compared to its corresponding liposomal formulation of ASOs. For example, Lip-Epi+ASOs against both resistances vs Lip-ASOs against both resistances.CC BY · PubMed Central
Figure 4 The effect of different treatments on the hMDR1 promoter activity and the intracellular accumulation of epirubicin in Caco-2 cells. (A) The effect of different treatments for 48 h on the hMDR1 promoter activity in Caco-2 cells. The luminescence was measured using a dual luciferase assay kit with a luminometer. After background correction, results were expressed as the level of hMDR1 promoter-pGL3 activity divided by pRL-TK activity level. * P<0.05 compared to CTR; † P<0.05 compared to Epi; ‡ P<0.05 when liposomal formulation compared to its corresponding free formulation; § P<0.05 when liposomal formulation of Epi plus ASOs compared to its corresponding liposomal formulation of ASO. (B) The effect of different treatments on the intracellular accumulation of fluorescent Epi in Caco-2 cells. The three-dimensional view of cell number versus fluorescence intensity of Caco-2 cells after different treatments was shown. (C) Mean fluorescence intensity of Epi control was normalized to be 100%. Mean fluorescence intensity of the other treatments was normalized relative to the Epi. Data are means ± standard deviation of four independent experiments. The relative fluorescence intensity % of formulations without Epi demonstrates that the auto-fluorescence of these treatments was negligible. † P<0.05 compared to Epi; ‡ P<0.05 compared to Lip-Epi; § P<0.05 compared to Lip-Epi+ASOs against pump resistance.
Figure 4 The effect of different treatments on the hMDR1 promoter activity and the intracellular accumulation of epirubicin in Caco-2 cells. (A) The effect of different treatments for 48 h on the hMDR1 promoter activity in Caco-2 cells. The luminescence was measured using a dual luciferase assay kit with a luminometer. After background correction, results were expressed as the level of hMDR1 promoter-pGL3 activity divided by pRL-TK activity level. * P<0.05 compared to CTR; † P<0.05 compared to Epi; ‡ P<0.05 when liposomal formulation compared to its corresponding free formulation; § P<0.05 when liposomal formulation of Epi plus ASOs compared to its corresponding liposomal formulation of ASO. (B) The effect of different treatments on the intracellular accumulation of fluorescent Epi in Caco-2 cells. The three-dimensional view of cell number versus fluorescence intensity of Caco-2 cells after different treatments was shown. (C) Mean fluorescence intensity of Epi control was normalized to be 100%. Mean fluorescence intensity of the other treatments was normalized relative to the Epi. Data are means ± standard deviation of four independent experiments. The relative fluorescence intensity % of formulations without Epi demonstrates that the auto-fluorescence of these treatments was negligible. † P<0.05 compared to Epi; ‡ P<0.05 compared to Lip-Epi; § P<0.05 compared to Lip-Epi+ASOs against pump resistance.CC BY · PubMed Central
Figure 5 The effect of different treatments on the mRNA levels of nonpump resistance associated genes and caspase activities. (A) The effect of different treatments on the mRNA levels of nonpump resistance associated genes, including BCL-2, BAX, and p53, as measured by real-time PCR. (B) The BAX:BCL-2 expression ratios of different treatments. (C) The effect of different treatments on the mRNA levels of apoptotic genes, including caspase 9 (CASP9), caspase 8 (CASP8), and caspase 3 (CASP3), as measured by real-time PCR. (D) The effect of different treatments on CASP3, 8, and 9 activities as recorded the luminescence using a luminometer. Means ± S.D. from three independent experiments are shown. * P<0.05 compared to CTR; † P<0.05 compared to Epi; ‡ P<0.05 when liposomal formulation compared to its corresponding free formulation; § P<0.05 when liposomal formulation of Epi plus ASOs compared to its corresponding liposomal formulation of ASO.
Figure 5 The effect of different treatments on the mRNA levels of nonpump resistance associated genes and caspase activities. (A) The effect of different treatments on the mRNA levels of nonpump resistance associated genes, including BCL-2, BAX, and p53, as measured by real-time PCR. (B) The BAX:BCL-2 expression ratios of different treatments. (C) The effect of different treatments on the mRNA levels of apoptotic genes, including caspase 9 (CASP9), caspase 8 (CASP8), and caspase 3 (CASP3), as measured by real-time PCR. (D) The effect of different treatments on CASP3, 8, and 9 activities as recorded the luminescence using a luminometer. Means ± S.D. from three independent experiments are shown. * P<0.05 compared to CTR; † P<0.05 compared to Epi; ‡ P<0.05 when liposomal formulation compared to its corresponding free formulation; § P<0.05 when liposomal formulation of Epi plus ASOs compared to its corresponding liposomal formulation of ASO.CC BY · PubMed Central
Figure 6 The effect of different treatments on the cell cycle distribution and DNA fragmentation in Caco-2 cells. (A) Analysis of cell number % of each cell cycle phase relative to total phases using flow cytometry in Caco-2 cells pretreated with different antisense formulations and/or Epi for 48 h. For example, sub-G1% is calculated as the percentage of the number of cells in the sub-G1 population relative to the number of total cells. Means ± S.D. from three independent experiments are shown. * P<0.05 compared to CTR; † P<0.05 compared to Epi; ‡ P<0.05 when liposomal formulation compared to its corresponding free formulation. (B) The DNA fragmentation effect of different treatments on Caco-2 cells for 48 h. DNA was isolated from Caco-2 cells and resolved by electrophoresis on 1.2% agarose gel. The gel was then visualized by SYBR safe staining. M: DNA marker; Lane 1: CTR; Lane 2: Epi; Lane 3: SCR; Lane 4: ASOs against pump resistance; Lane 5: ASOs against nonpump resistance; Lane 6: ASOs against both resistances; Lane 7: Lip; Lane 8: Lip-ASOs against pump resistance; Lane 9: Lip-Epi; Lane 10: Lip-ASOs against nonpump resistance; Lane 11: Lip-ASOs against both resistances; Lane 12: Lip-Epi+ASOs against pump resistance; Lane 13: Lip-Epi+ASOs against nonpump resistance; Lane 14: Lip-Epi+ASOs against both resistances.
Figure 6 The effect of different treatments on the cell cycle distribution and DNA fragmentation in Caco-2 cells. (A) Analysis of cell number % of each cell cycle phase relative to total phases using flow cytometry in Caco-2 cells pretreated with different antisense formulations and/or Epi for 48 h. For example, sub-G1% is calculated as the percentage of the number of cells in the sub-G1 population relative to the number of total cells. Means ± S.D. from three independent experiments are shown. * P<0.05 compared to CTR; † P<0.05 compared to Epi; ‡ P<0.05 when liposomal formulation compared to its corresponding free formulation. (B) The DNA fragmentation effect of different treatments on Caco-2 cells for 48 h. DNA was isolated from Caco-2 cells and resolved by electrophoresis on 1.2% agarose gel. The gel was then visualized by SYBR safe staining. M: DNA marker; Lane 1: CTR; Lane 2: Epi; Lane 3: SCR; Lane 4: ASOs against pump resistance; Lane 5: ASOs against nonpump resistance; Lane 6: ASOs against both resistances; Lane 7: Lip; Lane 8: Lip-ASOs against pump resistance; Lane 9: Lip-Epi; Lane 10: Lip-ASOs against nonpump resistance; Lane 11: Lip-ASOs against both resistances; Lane 12: Lip-Epi+ASOs against pump resistance; Lane 13: Lip-Epi+ASOs against nonpump resistance; Lane 14: Lip-Epi+ASOs against both resistances.CC BY · PubMed Central
Figure 7 Proposed pathways for reversing pump and nonpump MDR in Caco-2 cells. Cyt. c, cytochrome c.
Figure 7 Proposed pathways for reversing pump and nonpump MDR in Caco-2 cells. Cyt. c, cytochrome c.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 45

Metadata

Authors
Lo, Y.-L., & Liu, Y.
Affiliations
National University of Tainan (TW)
Corresponding author
Lo, Yu-Li
Venue
PLoS ONE
Published
2014-03-17
Volume
9
Issue
3
Pages
e90180
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1977619659
Cited by
45
References
44
Citations by year
2025: 3 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 7 · 2015: 4 · 2014: 4
FWCI
2.89
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Science Council (NSC 102-2320-B-024-002)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
multidrug resistance, PEGylated liposomes, antisense oligonucleotides, MDR1, MRP1, MRP2, Bcl-2, Bcl-xL, epirubicin, Caco-2 cells, colon adenocarcinoma, apoptosis, efflux pump inhibition, chemosensitization, p53, Bax
MeSH terms
Multidrug Resistance-Associated Protein 2, Cell Cycle, Humans, Liposomes, Polyethylene Glycols, Promoter Regions, Genetic, RNA, Messenger, Epirubicin, Gene Expression, Gene Expression Regulation, Neoplastic, Oligonucleotides, Antisense, Apoptosis, Genes, Reporter, Caco-2 Cells, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, ATP Binding Cassette Transporter, Subfamily B, Member 1, Caspases, Gene Silencing, ATP-Binding Cassette, Sub-Family C Proteins, bcl-X Protein, DNA Fragmentation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides. https://app.cochat.ai/papers/10.1371/journal.pone.0090180
The paper
Lo, Y.-L., & Liu, Y. (2014). Reversing Multidrug Resistance in Caco-2 by Silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL Using Liposomal Antisense Oligonucleotides. PLoS ONE. https://doi.org/10.1371/journal.pone.0090180

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.